Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Neurocrine (NBIX) and Dexcom (DXCM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX – Research Report), Neurocrine (NBIX – Research Report) and Dexcom (DXCM – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Boston Scientific (BSX)
J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Boston Scientific yesterday. The company’s shares closed last Friday at $74.73.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $108.52, which is a 45.0% upside from current levels. In a report issued on February 4, TipRanks – DeepSeek also upgraded the stock to Buy with a $101.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
In a report released yesterday, Danielle Brill from Truist Financial maintained a Buy rating on Neurocrine, with a price target of $140.00. The company’s shares closed last Friday at $124.12.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $181.50, representing a 46.6% upside. In a report issued on February 1, TipRanks – xAI also upgraded the stock to Buy with a $154.00 price target.
Dexcom (DXCM)
In a report released yesterday, Richard Newitter from Truist Financial maintained a Buy rating on Dexcom, with a price target of $80.00. The company’s shares closed last Friday at $70.02, close to its 52-week low of $62.34.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $86.19, representing a 33.7% upside. In a report issued on February 1, TipRanks – PerPlexity also upgraded the stock to Buy with a $84.00 price target.
